Related Experiment Video
Updated: May 30, 2026
07:48
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Novel agents for advanced bladder cancer
Guru Sonpavde1, Aymen A Elfiky, Jonathan E Rosenberg
1Genitourinary Oncology Program, Texas Oncology, Veterans Affairs Medical Center, Baylor College of Medicine, 501 Medical Center Blvd, Webster, TX 77598, USA.
Therapeutic Advances in Medical Oncology
|July 27, 2011
Summary
Advanced transitional cell carcinoma has poor long-term outcomes despite chemotherapy. Novel biologic agents and multidisciplinary approaches are crucial for improving salvage therapy and neoadjuvant treatments for bladder cancer.
Area of Science:
- Oncology
- Urology
- Pharmacology
Background:
- Advanced transitional cell carcinoma (TCC) shows high initial response rates but poor long-term survival with standard platinum-based chemotherapy.
- Salvage therapy for TCC currently has limited efficacy, representing a significant unmet clinical need.
- Neoadjuvant therapy before cystectomy is a key paradigm for muscle-invasive bladder cancer, offering opportunities for novel agent development.
Purpose of the Study:
- To review recent and ongoing clinical trials of novel chemotherapeutic and biologic agents for advanced bladder cancer.
- To highlight the importance of novel agents in improving outcomes for TCC, particularly in salvage and neoadjuvant settings.
- To emphasize the need for a multidisciplinary approach in advancing TCC treatment.
Main Methods:
- Review of current literature and ongoing clinical trials involving novel agents for TCC.
- Analysis of treatment strategies including neoadjuvant therapy and salvage options.
- Consideration of patient populations, including those unsuitable for cisplatin-based chemotherapy.
Main Results:
- Novel biologic agents show promise for improving outcomes in advanced TCC.
- Neoadjuvant therapy presents a valuable platform for evaluating new treatments.
- A collaborative, multidisciplinary approach is essential for therapeutic progress.
Conclusions:
- Improved salvage and neoadjuvant therapies are critical for advanced bladder cancer.
- Novel chemotherapeutic and biologic agents are key to enhancing long-term outcomes.
- Multidisciplinary collaboration is necessary to drive therapeutic innovation in TCC.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:30Urinary Tract Calculi III: Medical Management
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...